Alexion Pharmaceuticals, Inc.

Susan Faas McKnight

Russell P Rother

Katherine S Bowdish

Anke Kretz-Rommel

Jeremy P Springhorn

Dayang Wu

Yi Wang

Yan Yan

Roxanne Cofiell

Mayur Movalia

Andrea Illingworth

Hao Wang

Zhao Xue Yu

Kathrine S Bowdish

This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.

Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses

The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein.

Use of an anti-CD200 antibody for prolonging the survival of allografts

The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.

Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies

This application provides methods and compositions for modulating and/or depleting CD200 positive cells.

Antibodies to OX-2/CD200 and uses thereof

Growing community of inventors

Old Lyme, CT, United States of America

Susan Faas McKnight